Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
07.04.2025 03:58:29

Qiagen Sees Q1 Results Above View; Lifts FY25 Adj. EPS Outlook

(RTTNews) - Qiagen N.V. (QGEN) announced preliminary first-quarter of 2025 results that exceeded its outlook for both net sales and adjusted earnings per share, reflecting strong performances across many growth drivers. The company raised its adjusted earnings per share outlook for full-year 2025.

The company expects first quarter adjusted earnings per share to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 at constant exchange rates. Analysts expect the company to report earnings of $0.49 per share for the first quarter. Analysts' estimates typically exclude special items.

Net sales grew approximately 5% or 7% at constant exchange rates, to about $483 million in the first-quarter of 2025, surpassing the previously communicated outlook for about 3% CER growth or 4% CER core business excluding discontinued products such as NeuMoDx and Dialunox. Analysts expect revenue of $464.79 million for the quarter.

Qiagen raised its adjusted earnings per share outlook for full-year 2025 in light of the strong sales growth in the first quarter and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment.

Full-year 2025, the company now projects adjusted earnings per share to be about $2.35 at constant exchange rates, up from the prior outlook of about $2.28 at CER. Analysts expect the company to report earnings of $2.29 per share for fiscal year 2025. But the company reaffirmed its goal to improve the adjusted operating income margin to above 30% for the year.

Additionally, Qiagen now expects to reach the mid-term adjusted operating income margin goal of at least 31% well ahead of the original 2028 timeline, reflecting the stronger-than-anticipated improvements delivered during 2024 and 2025.

The company noted that it will provide additional perspectives on the outlook for full-year 2025 with the publication of the first quarter of 2025 results on May 7, 2025.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Analysen zu QIAGEN N.V.

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
07.02.24 QIAGEN Hold Jefferies & Company Inc.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 Knaller-Aktien im BX Musterportfolio📈: Thales, Generali & Swiss Life mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt:
📌 Thales Group (FR0000121329)
📌 Assicurazioni Generali (IT0000062072)
📌 Swiss Life Holding (CH0014852781)

➡️ Ausserdem zeigen wir, welche Aktien das Portfolio verlassen haben und warum:
❌ Meta Platforms (US30303M1027)
❌ LPL Financial (US50212V1008)
❌ American Express (US0258161092)

Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien im BX Musterportfolio📈: Thales, Generali & Swiss Life | Rebalancing im #BXMusterportfolio

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’324.13 18.31 B7RS6U
Short 12’563.51 13.42 BKFSAU
Short 12’999.96 8.91 BVKSPU
SMI-Kurs: 12’253.79 02.05.2025 17:30:15
Long 11’640.00 19.68
Long 11’100.00 13.97
Long 10’640.00 7.42
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}